Mandate

Vinge advises Artimplant in connection with new share issue

August 03, 2010

The board of directors of Artimplant AB (publ) has resolved to recommend that an extraordinary shareholders’ meeting adopt a resolution in respect of a rights issue to the existing members in order to provide the company with SEK 40,000,000 after issue costs.

Artimplant is listed on NASDAQ OMX Stockholm.

Vinge’s team primarily consisted of responsible partner Anders Strid and associates Anna Björk Larson and Emma Kero Ljungberg.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025